We are comparing standard alectinib dosing to a personalized dosing method based on blood levels for patients with specific alectinib concentrations. The goal is to see if personalized dosing improves treatment outcomes and safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
ALK positive non-small cell lung cancer (NSCLC) is a type of lung cancer that occurs when there is a mutation in the ALK gene, leading to uncontrolled cell growth. This condition is often treated with targeted therapies that specifically address the ALK mutation.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.